FSSAI ne Nestle aur Dr. Reddy’s jaise bade brands ko **150** se zyada notices bheje hain. Mamla hai 'misleading health claims' ka, jiske chalte ab investors ki nazar regulators par tiki hai.
Regulator ka strict rukh
Food Safety and Standards Authority of India (FSSAI) ne health supplement aur FMCG sector mein hulchul macha di hai. Regulator ne 150 se zyada food manufacturers aur kam se kam 12 e-commerce platforms ko notice thama diye hain. Inse pucha gaya hai ki jo 'immunity', 'protein' ya 'muscle growth' ke bade-bade daave packet par kiye gaye hain, unka proof kya hai?
Nestle aur peers par nazar
Nestle India ka naam sabse upar aa raha hai, khaaskar unke infant nutrition products jaise 'NAN Excella Pro Stage 1' aur 'Lactogen Pro' ko lekar. September mein jab ye khabar aayi thi, tab share price mein lagbhag 3% ki girawat dekhi gayi thi. Company ka kehna hai ki wo rules follow kar rahe hain, par Nestle ke saath-saath Dr. Reddy’s Laboratories aur Tirupati Wellness ko bhi apne claims prove karne honge.
E-commerce platforms bhi lapet mein
Sirf manufacturers hi nahi, Amazon, Flipkart aur Netmeds jaise platforms ko bhi notice mila hai. Iska matlab saaf hai—ab online bikne wale har health product ki zimmedari in platforms ki bhi hogi. Regulatory environment sakth ho raha hai, jiska asar seedha compliance costs aur marketing strategies par pad sakta hai.
Investors ke liye kya hai risk?
Agar in companies ko apne packaging ya ads badalne pade, toh short-term mein marketing disruption aur extra cost aana tay hai. Investors ko ab upcoming quarterly results aur management ki commentary par nazar rakhni hogi ki wo in cases ko kaise handle karte hain. Kya ye brand value ko nuksan pahunchayega? Yehi ab sabse bada sawal hai.